Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitors

Evacetrapib is an investigational cholesteryl ester transfer protein inhibitor (CETPi) for reduction of risk of major adverse cardiovascular events in patients with high-risk vascular disease. Understanding evacetrapib disposition, metabolism, and the potential for drug–drug interactions (DDI) may h...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pharmacol Res Perspect
Main Authors: Cannady, Ellen A, Wang, Ming-Dauh, Friedrich, Stuart, Rehmel, Jessica L F, Yi, Ping, Small, David S, Zhang, Wei, Suico, Jeffrey G
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Ltd 2015
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4618649/
https://ncbi.nlm.nih.gov/pubmed/26516590
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.179
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados